HOME >> MEDICINE >> NEWS
Defibrillators may improve survival in non-ischemic cardiomyopathy

Research from Northwestern University suggests that implantable cardioverter defibrillators (ICDs) can improve the survival rate of people who have a weakened heart muscle caused by factors unrelated to coronary artery disease a condition known as non-ischemic cardiomyopathy. Previous studies showed that people whose heart muscle had been weakened as a result of coronary artery disease (ischemic cardiomyopathy) could benefit from ICDs. This research is among the first to indicate that the approximately 200,000 other Americans who suffer from this condition may also benefit.

An ICD is a small device implanted under the skin near the collarbone and connected to the heart with insulated wires called leads. ICDs deliver shocks and other electrical therapies to the ventricles to stop ventricular tachyarrhythmias (abnormally fast heart rhythms originating in the heart's lower chambers).

Initial results from the DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation) ICD were presented today at the American Heart Association's Scientific Sessions 2003 conference in Orlando, Florida by principal investigator Alan Kadish, M.D., Chester D. and Deborah M. Cooley Professor of Medicine from Feinberg School of Medicine at Northwestern University in Chicago.

The DEFINITE study, initiated in May 1998, followed 458 participants at 48 medical centers in the United States and Israel. Participants were randomized into two groups -- one receiving standard heart failure drug therapy (control group) and the other receiving drug therapy plus an implant of a St. Jude Medical ICD. The goal was to evaluate whether the ICDs offered an overall survival benefit to those who received them.

During the study, overall mortality at two years was 13.8 percent in the standard therapy (control) group versus 8.1 percentin the ICD group. Though these results did not reach the level of statistical significance defined in the study protocol, they do show
'"/>

Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
11-Nov-2003


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. New technique shows promise for improved straightening of crooked nose
3. Balance and better interactions between primary-care and specialist physicians improve US health
4. Cornea transplants can be improved
5. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
6. New treatment options for some difficult cancers improve survival and quality of life
7. New substance that improves the photodetection of bladder cancer gains market approval
8. Most advanced CT scanner improves imaging of heart, avoids need for surgical inspection
9. Increasing physician volume requirement could improve mammogram accuracy, study concludes
10. Columbia study finds hemophilia therapy dramatically improves outcomes for bleeding stroke
11. OHSU scientists develop MRI approach to improve breast cancer detection

Post Your Comments:
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
Cached News: